Literature DB >> 28527052

Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients.

Carlo Lovati1, Luca Giani2.   

Abstract

In the past few decades, the so-feared botulinum toxin has conversely acquired the role of a ever more versatile therapeutic substance, used in an increasing number of pathological situations, including chronic headache and more precisely in the prophylaxis of chronic migraine. The medical use of botulinum toxin allowed to better understand its multiple mechanisms of action. Investigations about the pathophysiology of primary and secondary headaches has shown a series of common biological elements that frequently are also targets of the action of botulinum toxin. These increasing evidences allowed to identify some biochemical, neurophysiological and radiological markers that may be useful in the individuation of patients which probably will respond to the treatment with Onabotulinum toxin-A among chronic migraineurs. These predictors include CGRP plasmatic levels, specific laser-evoked potential responses, peculiar brain MRI and fMRI and characteristic clinical manifestations. Unfortunately, at now, these predictors are still not available for the clinical practice. Furthermore, the better knowledge about biology of headaches and regarding botulinum toxin activities may also help in directing investigations on the possible use of Onabotulinum toxin-A in other headaches different from migraine. This review tries to show in detail these biological mechanisms and their implication in selecting patients eligible for the treatment with Onabotulinum toxin-A.

Entities:  

Keywords:  CGRP; Headache; Migraine; Onabotulinum toxin-A; TRP

Mesh:

Substances:

Year:  2017        PMID: 28527052     DOI: 10.1007/s10072-017-2884-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  54 in total

1.  Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.

Authors:  M J Welch; J R Purkiss; K A Foster
Journal:  Toxicon       Date:  2000-02       Impact factor: 3.033

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

Review 3.  Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.

Authors:  Peter J Goadsby
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Reduced habituation to experimental pain in migraine patients: a CO(2) laser evoked potential study.

Authors:  M Valeriani; M de Tommaso; D Restuccia; D Le Pera; M Guido; G D Iannetti; G Libro; A Truini; G Di Trapani; F Puca; P Tonali; G Cruccu
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

5.  Induction of calcitonin gene-related peptide expression in rats by cortical spreading depression.

Authors:  Yan Wang; Anne E Tye; Junli Zhao; Dongqing Ma; Ann C Raddant; Fan Bu; Benjamin L Spector; Nolan K Winslow; Minyan Wang; Andrew F Russo
Journal:  Cephalalgia       Date:  2016-11-12       Impact factor: 6.292

6.  Analysis of Drosophila TRPA1 reveals an ancient origin for human chemical nociception.

Authors:  Kyeongjin Kang; Stefan R Pulver; Vincent C Panzano; Elaine C Chang; Leslie C Griffith; Douglas L Theobald; Paul A Garrity
Journal:  Nature       Date:  2010-03-17       Impact factor: 49.962

Review 7.  Botulinum toxin and the treatment of headache: A clinical review.

Authors:  Alan G Finkel
Journal:  Toxicon       Date:  2015-09-10       Impact factor: 3.033

8.  Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons.

Authors:  Fumimasa Amaya; Kentaro Oh-hashi; Yoshihisa Naruse; Norio Iijima; Masashi Ueda; Goshun Shimosato; Makoto Tominaga; Yoshifumi Tanaka; Masaki Tanaka
Journal:  Brain Res       Date:  2003-02-14       Impact factor: 3.252

Review 9.  Treatment of tension-type headache with botox: a review of the literature.

Authors:  Dima Rozen; Joyti Sharma
Journal:  Mt Sinai J Med       Date:  2006-01

10.  CGRPα-expressing sensory neurons respond to stimuli that evoke sensations of pain and itch.

Authors:  Eric S McCoy; Bonnie Taylor-Blake; Mark J Zylka
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

View more
  7 in total

1.  A new target for the treatment of trigeminal neuralgia with botulinum toxin type A.

Authors:  Chuanjie Wu; Nanchang Xie; Hongbo Liu; Haifeng Zhang; Lu Zhang; Yajun Lian
Journal:  Neurol Sci       Date:  2017-10-30       Impact factor: 3.307

2.  News on the journal Neurological Sciences in 2017.

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2018-01       Impact factor: 3.307

3.  Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China.

Authors:  Xiao-Bo Fang; Meng-Shu Xie; Zu-Biao Song; Zhi-Gang Zhong; Ying Wang; Zi-Lin Ou; Chao Dang; Ling Li; Wei-Xi Zhang
Journal:  Neurol Sci       Date:  2019-11-19       Impact factor: 3.307

4.  An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders.

Authors:  Gao Yunfeng; Lai Fei; Liu Junbo; Yang Dingyuan; Huang Chaoyou
Journal:  Int Urol Nephrol       Date:  2022-01-19       Impact factor: 2.370

5.  Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine.

Authors:  Paola Sarchielli; Michele Romoli; Ilenia Corbelli; Laura Bernetti; Angela Verzina; Elona Brahimi; Paolo Eusebi; Stefano Caproni; Paolo Calabresi
Journal:  Front Neurol       Date:  2017-12-04       Impact factor: 4.003

6.  Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis.

Authors:  Antonella Giannantoni; Marilena Gubbiotti; Vittorio Bini
Journal:  Toxins (Basel)       Date:  2019-08-30       Impact factor: 4.546

7.  Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine.

Authors:  Elisa Dini; Sonia Mazzucchi; Ciro De Luca; Martina Cafalli; Lucia Chico; Annalisa Lo Gerfo; Gabriele Siciliano; Ubaldo Bonuccelli; Filippo Baldacci; Sara Gori
Journal:  Toxins (Basel)       Date:  2019-10-19       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.